Literature DB >> 6723041

Automated amidolytic method for determining heparin, a heparinoid, and a low-Mr heparin fragment, based on their anti-Xa activity.

H ten Cate, R J Lamping, C P Henny, A Prins, J W ten Cate.   

Abstract

Using the chromogenic substrate S-2222, we have optimized and automated an amidolytic assay for heparin. The assay is based on the detection of anti-Xa activity generated by heparin in plasma. The method is reproducible (intra- and interassay CVs of 2.4 and 3.3%, respectively) and reliable in antithrombin III-deficient plasma. Results of this assay, obtained for plasma samples from patients and volunteers treated with heparin, correlate well (r = 0.899) with those of the test for activated partial thromboplastin time. Upon administration of a low-Mr heparinoid (Org 10172) and heparin fragment ( Kabi 2165), however, the activated partial thromboplastin time failed to detect anticoagulant activity, whereas the chromogenic heparin assay revealed anti-Xa activity. This automated amidolytic assay for heparin is therefore suitable not only for monitoring standard therapy with heparin but also for measuring the activity of recently developed heparin fractions.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6723041

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  6 in total

1.  In vivo treatment of rats with unfractionated heparin (UFH) or low molecular weight heparin (LMWH) does not affect experimentally induced colon carcinoma metastasis.

Authors:  S M Smorenburg; R Vink; M te Lintelo; W Tigchelaar; A Maas; H R Büller; C J van Noorden
Journal:  Clin Exp Metastasis       Date:  1999-07       Impact factor: 5.150

2.  Novel method for measurement of heparin anticoagulant activity using SPR.

Authors:  Jing Zhao; Xinyue Liu; Anju Malhotra; Quanhong Li; Fuming Zhang; Robert J Linhardt
Journal:  Anal Biochem       Date:  2017-03-18       Impact factor: 3.365

Review 3.  Heparin-Induced thrombocytopenia: minimising the risks in the elderly patient.

Authors:  B Tardy-Poncet; B Tardy
Journal:  Drugs Aging       Date:  2000-05       Impact factor: 3.923

Review 4.  Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.

Authors:  M I Wilde; A Markham
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

5.  Low molecular weight heparin as an adjunct to thrombolysis for acute myocardial infarction: the FATIMA study. Fraxiparin Anticoagulant Therapy in Myocardial Infarction Study Amsterdam (FATIMA) Study Group.

Authors:  S A Chamuleau; R J de Winter; M Levi; R Adams; H R Büller; M H Prins; K I Lie; R J Peters
Journal:  Heart       Date:  1998-07       Impact factor: 5.994

6.  Release characteristics of enoxaparin sodium-loaded polymethylmethacrylate bone cement.

Authors:  Hui Sun; Xinzhe Ma; Zhiyong Li; Jianning Liu; Wei Wang; Xiangbei Qi
Journal:  J Orthop Surg Res       Date:  2021-02-04       Impact factor: 2.359

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.